IP Library › Patent Application 13231630
Patent Application
App. No. 13/231,630

METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/231,630
Abstract

The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compounds or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate.

Claims (50)

1 . A method for treating a skin cancer; treating cancer of an organ; treating leukemia; improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salts thereof:

wherein the compound of Formula (I) is:

wherein:

X is a hydrogen, an organic cation or an inorganic cation;

n is an integer from 1 to 2; and

m is an integer from 1 to 2.

2 . The method of claim 1 , further comprising administering a pharmaceutically acceptable carrier.

3 . The method of claim 1 , wherein the compound of Formula (I) is selected from the group consisting of:

2,5-dihydroxybenzene sulfonic acid;

calcium 2,5-dihydroxybenzenesulfonate;

potassium 2,5-dihydroxybenzenesulfonate;

magnesium 2,5-dihydroxybenzenesulfonate; and

diethylamine 2,5-dihydroxybenzenesulfonate.

4 . The method of claim 1 , further comprising at least one therapeutic agent.

5 . The method of claim 4 , wherein the therapeutic agent is a chemotherapeutic agent, a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a NMDA receptor antagonist, an endothelin antagonist, an immunomodulating agent, a vitamin D analogue, salicylic acid, or a combination of two or more thereof.

6 . The method of claim 5 , wherein the therapeutic agent is selected from the group consisting of a chemotherapeutic agent, a steroid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a NMDA receptor antagonist, an endothelin antagonist and an immunomodulating agent.

7 . The method of claim 1 , wherein the skin cancer is basal cell cacinoma, squamous cell carcinoma, a melanoma, a keratoacanthoma, an actinic keratosis, a Bowen's disease verrucae, sarcomas orangiosarcoma.

8 . The method of claim 1 , wherein the compound of Formula (I) is administered orally, bucally, parenterally, by inhalation, by topical application or rectally.

9 . A method for treating rosacea in a patient in need thereof comprising topically administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salts thereof:

wherein the compound of Formula (I) is:

wherein:

X is a hydrogen, an organic cation or an inorganic cation;

n is an integer from 1 to 2; and

m is an integer from 1 to 2.

10 . The method of claim 9 , further comprising administering a pharmaceutically acceptable carrier.

11 . The method of claim 9 , wherein the compound of Formula (I) is selected from the group consisting of:

2,5-dihydroxybenzene sulfonic acid;

calcium 2,5-dihydroxybenzenesulfonate;

potassium 2,5-dihydroxybenzenesulfonate;

magnesium 2,5-dihydroxybenzenesulfonate; and

diethylamine 2,5-dihydroxybenzenesulfonate.

12 . The method of claim 9 , further comprising at least one therapeutic agent.

13 . The method of claim 12 , wherein the therapeutic agent is a chemotherapeutic agent, a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a NMDA receptor antagonist, an endothelin antagonist, an immunomodulating agent, a vitamin D analogue, salicylic acid, or a combination of two or more thereof.

14 . The method of claim 13 , wherein the therapeutic agent is selected from the group consisting of a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a vitamin D analogue and salicylic acid.

15 . A method for treating psoriasis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salts thereof and at least one therapeutic agent:

wherein the compound of Formula (I) is:

wherein:

X is a hydrogen, an organic cation or an inorganic cation;

n is an integer from 1 to 2; and

m is an integer from 1 to 2.

16 . The method of claim 15 , further comprising administering a pharmaceutically acceptable carrier.

17 . The method of claim 15 , wherein the compound of Formula (I) is selected from the group consisting of:

2,5-dihydroxybenzene sulfonic acid;

calcium 2,5-dihydroxybenzenesulfonate;

potassium 2,5-dihydroxybenzenesulfonate;

magnesium 2,5-dihydroxybenzenesulfonate; and

diethylamine 2,5-dihydroxybenzenesulfonate.

18 . The method of claim 15 , wherein the therapeutic agent is a chemotherapeutic agent, a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a NMDA receptor antagonist, an endothelin antagonist, an immunomodulating agent, a vitamin D analogue, salicylic acid, or a combination of two or more thereof.

19 . The method of claim 18 , wherein the therapeutic agent is selected from the group consisting of a steroid, a retinoid, an antimicrobial compound, an antioxidant, an anti-inflammatory compound, a Vitamin D analogue and salicylic acid.

20 . The method of claim 15 , wherein the compound of Formula (I) and the therapeutic agent are administered orally, bucally, parenterally, by inhalation, by topical application or rectally.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2011
From: ACTION MEDICINES, S.L.
To: AMDERMA PHARMACEUTICALS, LLC
Reel/Frame 027254/0391 →